- Demant forecasts its organic revenue for the full year to be at the lower end of +1% to +3%.
- The company expects Earnings Before Interest and Taxes (EBIT) to be between DKK3.90 billion and DKK4.30 billion.
- For the third quarter, Demant’s revenue stood at DKK5.45 billion, marking a 1% increase year-over-year.
- The global hearing aid market’s unit growth is anticipated to be between 2% and 4% in 2025.
- The average selling price (ASP) in the hearing aid market is expected to decline by around 1% for the full year.
- Despite ASP decline, the overall market value growth rate is projected to be between 1% and 3% for 2025.
- The French market is expected to grow substantially, with unit growth in the high single digits for 2025.
- Demant has allocated a higher-than-normal amount of cash to acquisitions in 2025, influenced by several bolt-on acquisitions and the acquisition of KIND.
- Operational expenditures (OPEX) are expected to remain flat in the second half of 2025 compared to the first half.
- Adverse exchange rate developments are projected to negatively impact EBIT by approximately DKK -125 million.
- Tariffs are expected to have a limited financial impact, costing around DKK -25 million for the Diagnostics business in 2025.
- Analyst recommendations include 15 buys, 7 holds, and 1 sell for Demant’s stock.
William Demant Holding A/S on Smartkarma
Analysts on Smartkarma have been closely monitoring William Demant Holding A/S, with Baptista Research recently providing an insightful coverage on the company. In their report titled “Demant A/S: Initiation of Coverage- Can AI-Powered Hearing Tech Disrupt the Global Market?“, Baptista Research discusses the company’s latest financial results for 2024. The report highlights a mixed performance by Demant, with an overall revenue growth of 4% driven by both organic growth and acquisitions, totaling DKK 22.4 billion. While there was a 5% improvement in gross profit, the EBIT experienced a slight decrease of about 2% (DKK 100 million) from the prior year, indicating some challenges encountered during the fiscal period.
A look at William Demant Holding A/S Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
William Demant Holding A/S, a company specializing in products for individuals with hearing loss, has a mixed outlook based on Smartkarma Smart Scores. While the company shows strong potential for growth and resilience, its value and dividend scores are lower. With a growth score of 4 and a resilience score of 3, William Demant Holding A/S is positioned well for future expansion and able to navigate challenges effectively. However, the company’s value score of 2 and dividend score of 1 indicate that investors may need to carefully consider these factors when evaluating the stock.
Demant A/S, the parent company of William Demant Holding A/S, focuses on developing, manufacturing, and selling a range of products to aid individuals with hearing loss in communication. Their product line includes hearing devices, implants, diagnostic instruments, and personal communication tools, serving a global customer base. With a diversified portfolio catering to the needs of those with hearing impairments, Demant A/S is at the forefront of providing innovative solutions in the healthcare industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
